Prognostic Value of Matrix Metalloproteinase 9 (MMP9) in Patients Following Off-Pump Coronary Artery Bypass Grafting

Prognostic Value of Matrix Metalloproteinase 9 (MMP9) in Patients Following Off-Pump Coronary Artery Bypass Grafting

Background: Matrix metalloproteinase 9 (MMP9) has recently emerged as a risk predictor in patients with cardiovascular diseases (CVD). However, little is known regarding the significance of elevated plasma MMP9 levels in patients during the long-term period following myocardial revascularisation. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Mikhail Popov, Siarhei Dabravolski, Vladislav Dontsov, Sergei Vzvarov, Evgeniy Agafonov, Dmitriy Zybin, Olga Radchenkova, Dmitriy Saveliev, Victoria Pronina, Natalia Kashirina, Liudmila Lipatova, Mikhail Peklo, Pavel Rutkevich, Elena Yanushevskaya, Alisa Sokolovskaya, Arkadiy Metelkin, Svetlana Verkhova, Nikita Nikiforov, Dmitriy Shumakov
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Life
Subjects:
ischaemic heart disease
matrix metalloproteinase 9 (MMP9)
biomarker
myocardial revascularisation
Online Access:https://www.mdpi.com/2075-1729/15/6/908
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Matrix metalloproteinase 9 (MMP9) has recently emerged as a risk predictor in patients with cardiovascular diseases (CVD). However, little is known regarding the significance of elevated plasma MMP9 levels in patients during the long-term period following myocardial revascularisation. We aimed to investigate the role of MMP9 in relation to myocardial status before and after myocardial revascularisation and to assess its long-term prognostic value. Methods: This prospective observational study included 200 male patients with ischaemic heart disease. All patients underwent direct myocardial revascularisation on a beating heart (off-pump surgery). Plasma MMP9 levels were analysed preoperatively, at 48 h postoperatively, and during the long-term follow-up period (one year postoperatively). Key echocardiographic parameters, specifically left ventricular ejection fraction (LVEF) and Left Ventricular End-Diastolic Volume (LVEDV), were also assessed. Results: MMP9 levels decreased significantly at 48 h postoperatively (<i>p</i> < 0.0001). During the long-term postoperative period, a clear relationship was demonstrated: higher 1-year MMP9 levels were associated with lower 1-year LVEF, whilst lower 1-year MMP9 levels were associated with higher 1-year LVEF. No significant correlation was observed between preoperative MMP9 levels and age or most other baseline laboratory parameters. Conclusions: Our study established an association between 1-year postoperative MMP9 levels and key parameters of left ventricular function during the long-term follow-up period. This suggests that MMP9 may serve as a novel biomarker for predicting outcomes following myocardial revascularisation.
ISSN:2075-1729

Similar Items